1. Home
  2. SIDU vs KLRS Comparison

SIDU vs KLRS Comparison

Compare SIDU & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sidus Space Inc.

SIDU

Sidus Space Inc.

HOLD

Current Price

$4.37

Market Cap

151.0M

ML Signal

HOLD

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$6.41

Market Cap

144.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SIDU
KLRS
Founded
2012
2019
Country
United States
United States
Employees
N/A
20
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.0M
144.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SIDU
KLRS
Price
$4.37
$6.41
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$19.00
AVG Volume (30 Days)
28.4M
80.5K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
66.94
N/A
EPS
N/A
N/A
Revenue
$3,383,878.00
N/A
Revenue This Year
$171.29
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$2.14
52 Week High
$5.99
$11.88

Technical Indicators

Market Signals
Indicator
SIDU
KLRS
Relative Strength Index (RSI) 56.46 45.92
Support Level $0.89 $4.35
Resistance Level $4.40 $7.18
Average True Range (ATR) 0.83 0.64
MACD 0.16 0.17
Stochastic Oscillator 59.02 64.02

Price Performance

Historical Comparison
SIDU
KLRS

About SIDU Sidus Space Inc.

Sidus Space Inc is a Space and Defense as-a-Service company focused on providing complex space hardware, satellite/spacecraft design, manufacture, launch, and data solutions for both government and commercial in-space missions for all destinations through the solar system. This includes a Space-based infrastructure of multi-mission satellites with hyperspectral, multi-spectral, and other sensors to provide monitoring services and solutions to multiple sectors and industries. The company supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers.

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

Share on Social Networks: